EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Phase 2 Trial of 89 Zr-Deferoxamine-Daratumumab for CD38-targeted Immuno-PET/CT Detection of Multiple Myeloma

Gary A Ulaner iD, Russ A Kuker iD, Benjamin Diamond iD, James Hoffman, Pooja Motwani, Ben Goldenson iD, Yaser Homsi, Gary Schiller, Beth Thomsen iD, Alanna Vossen iD, Dickran Kazandjian iD, C Ola Landgren

Radiology · 01.11.2026 · 321 (2)

DOI: 10.1148/radiol.260517 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Radiology, erschienen am 01.11.2026. Verfasst von Gary A Ulaner und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Imaging and Therapy, Hoag Family Cancer Institute, 16105 Sand Canyon Ave, Irvine, CA 92618. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Zirconium, Multiple Myeloma, ADP-ribosyl Cyclase 1. Die Arbeit nennt 27 Literaturangaben. Gefördert von: National Institutes of Health, Sylvester Comprehensive Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In participants with multiple myeloma, CD38-targeted zirconium 89 deferoxamine-daratumumab immuno-PET/CT helped detect active myeloma, even in some participants with no signs of disease at fluorine 18 fluorodeoxyglucose PET/CT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyZirconiumMultiple MyelomaADP-ribosyl Cyclase 1RadioisotopesDeferoxamineAntibodies, MonoclonalHumansFemaleProspective StudiesMiddle AgedAgedMaleFluorodeoxyglucose F18Radiopharmaceuticals

Substanzen

ZirconiumADP-ribosyl Cyclase 1RadioisotopesZirconium-89DeferoxaminedaratumumabAntibodies, MonoclonalFluorodeoxyglucose F18Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Molecular Imaging and Therapy, Hoag Family Cancer Institute, 16105 Sand Canyon Ave, Irvine, CA 92618.
  • Department of Radiology and Cancer Biology, University of Southern California, Los Angeles, Calif.
  • Department of Radiology, University of Miami Miller School of Medicine, Miami, Fla.
  • Sylvester Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Fla.
  • Department of Medical Oncology, Hoag Family Cancer Institute, Irvine, Calif.
  • Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, Calif.

ORCID-Profile: Gary A Ulaner, Russ A Kuker, Benjamin Diamond, Ben Goldenson, Beth Thomsen, Alanna Vossen, Dickran Kazandjian

Förderung

  • National Institutes of Health
  • Sylvester Comprehensive Cancer Center

Zitieren

APA

Ulaner, G. A., Kuker, R. A., Diamond, B., Hoffman, J., Motwani, P., Goldenson, B., Homsi, Y., Schiller, G., Thomsen, B., Vossen, A., Kazandjian, D., & Landgren, C. O. (2026). Phase 2 Trial of 89 Zr-Deferoxamine-Daratumumab for CD38-targeted Immuno-PET/CT Detection of Multiple Myeloma. Radiology, 321(2). https://doi.org/10.1148/radiol.260517

Vancouver

Ulaner GA, Kuker RA, Diamond B, Hoffman J, Motwani P, Goldenson B, et al. Phase 2 Trial of 89 Zr-Deferoxamine-Daratumumab for CD38-targeted Immuno-PET/CT Detection of Multiple Myeloma. Radiology. 2026;321(2). doi:10.1148/radiol.260517

BibTeX
@article{Ulaner2026,
  author = {Ulaner, Gary A and Kuker, Russ A and Diamond, Benjamin and Hoffman, James and Motwani, Pooja and Goldenson, Ben and Homsi, Yaser and Schiller, Gary and Thomsen, Beth and Vossen, Alanna and Kazandjian, Dickran and Landgren, C Ola},
  title = {Phase 2 Trial of 89 Zr-Deferoxamine-Daratumumab for CD38-targeted Immuno-PET/CT Detection of Multiple Myeloma},
  journal = {Radiology},
  year = {2026},
  volume = {321},
  number = {2},
  doi = {10.1148/radiol.260517}
}
Kostenlos starten →